| Revenue growth | 22% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 24.1%, down from 31.8% YoY. |
| Demand visibility | Strong demand in International and India branded formulations. |
Growth
Revenue reached Rs. 80,170 mn (+22% YoY). Reported PAT fell 35.9% YoY to Rs. 9,398 mn.
Outlook
Organic capex of Rs. 5,852 mn this quarter. Focus on specialty portfolio and new US launches.
Risks
EBITDA margin contracted 770 bps YoY to 24.1%. Net debt increased to Rs. 59,041 mn.
Last quarter's promises, checked
Delivered
- Guided high teens revenue growth → delivered 22% YoY (= BEAT)
- Guided margins in excess of 24% → delivered 24.1% (= BEAT)
- Guided India outperformance vs IPM → delivered outpaced market (= BEAT)
Partly delivered
- Guided single digit US growth → delivered growth driven by 11 launches (= PARTIAL)
Investor Presentation filed with BSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,154.00
- Market cap
- ₹1,16,119 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 25.7×Sector 47.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences announced positive Phase II(b) clinical trial results for Saroglitazar Mg in MASH. The global study successfully met its primary endpoint of resolution of steatohepatitis.
- Execution
- 52 weeks
Zydus Lifesciences Merger & Restructuring Worth ₹5 Cr
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City, Gujarat. The subsidiary has a paid-up capital of Rs. 5 Crore.
- Value
- ₹5.00 Cr
Zydus Lifesciences Promoter Buying (Off-Market)
Zydus Lifesciences announced the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel to Mr. Prashant Babubhai Patel, both within the Promoter Group.